Armistice Capital LLC Makes New $941,000 Investment in Bionomics Limited (NASDAQ:BNOX)

Armistice Capital LLC purchased a new stake in Bionomics Limited (NASDAQ:BNOX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned 0.15% of Bionomics at the end of the most recent quarter.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Bionomics in a report on Thursday, August 1st.

Bionomics Price Performance

Shares of BNOX opened at $0.63 on Friday. The stock’s fifty day moving average is $0.65 and its 200-day moving average is $0.81. Bionomics Limited has a one year low of $0.50 and a one year high of $6.41.

Bionomics Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.